Azithromycin: can its benefit be ruled out in mild COVID-19?
Lancet Respir Med
.
2021 Oct;9(10):1079-1081.
doi: 10.1016/S2213-2600(21)00289-7.
Epub 2021 Jul 9.
Author
Alejandro Rodríguez-Molinero
1
Affiliation
1
Àrea de Recerca, Consorci Sanitari de l'Alt Penedès i Garraf, Vilafranca del Penedès, Barcelona 08720, Spain. Electronic address: arodriguez@csapg.cat.
PMID:
34252379
PMCID:
PMC8270520
DOI:
10.1016/S2213-2600(21)00289-7
No abstract available
Publication types
Comment
MeSH terms
Azithromycin*
COVID-19 Drug Treatment*
Humans
SARS-CoV-2
Substances
Azithromycin